Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Helix BioPharma Corp.TSX: HBP.TO
Short-term Debt · Q3 FY2026 · quarter ended Apr 2026
Short-term debt remains negative
Q3 FY2026 short-term debt was CA$359K, compared with CA$0 a year earlier. Over 3 fiscal years it compounded at -48.6% a year.
Context
- Short-term debt amounted to 1.7% of total assets at the end of Q3 FY2026, up 1.7 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
CAD · from the balance sheet
- Latest · FY2025
- 335K CAD
- Year-over-year change
- —
- 4-year CAGR
- -36.2%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 335K | — |
| FY2024 | 2024-07-31 | 0 | — |
| FY2023 | 2023-07-31 | 0 | -100.0% |
| FY2022 | 2022-07-31 | 2.47M | +21.7% |
| FY2021 | 2021-07-31 | 2.03M | — |
Short-term Debt vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
- Short-term debt amounts to 1.7% of total assets for HBP.TO, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.25M USD | -19.3% | -30.8% | 3.2% | |
| Apr 2026 | CA$2.22M CAD | -34.8% | — | 144.9% | |
| Apr 2026 | CA$359K CAD | — | -48.6% | 1.7% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Peer median (excluding HBP.TO) | — | -34.8% | -30.8% | 1.6% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.